The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Skin Cancer Market Research Report 2024
Synopsis
Skin cancer is the most common type of cancer, which arise due to uncontrolled growth of abnormal skin cells. It occurs when skin cells are damaged by unrepaired DNA or genetic defects that lead the uncontrolled growth of cells in the skin.
The global Skin Cancer market was valued at US$ 502.4 million in 2023 and is anticipated to reach US$ 727 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
Increasing incidence of skin cancer: The incidence of skin cancer is increasing worldwide, primarily due to the rise in UV exposure, aging population, and increasing awareness about skin cancer prevention and early detection. This has led to an increase in the demand for skin cancer treatment options, thereby driving the market growth.
Advances in skin cancer treatment: The development of new and innovative treatment options for skin cancer, including targeted therapies and immunotherapies, has significantly improved patient outcomes and increased the survival rates. These advancements have driven the demand for skin cancer drugs and treatment options, fueling market growth.
Rising awareness about skin cancer: The increasing awareness about skin cancer and its prevention methods has led to a significant increase in the diagnosis and treatment rates. This has propelled the demand for skin cancer drugs and treatment options, further driving market growth.
Exponential growth in the aging population: The aging population is more susceptible to skin cancer due to prolonged exposure to UV rays and other environmental factors. The rise in the aging population has led to an increase in the demand for skin cancer treatment options, fueling market growth.
Increasing health care expenditure: With the improving economy and increasing disposable income in many countries, health care expenditure is on the rise. This has led to an increase in the demand for skin cancer drugs and treatment options, further driving market growth.
This report aims to provide a comprehensive presentation of the global market for Skin Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Skin Cancer.
Report Scope
The Skin Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Skin Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Skin Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
Sun Pharma
Elekta
Varian Medical Systems
Cannabis Science
Cellceutix
LEO Pharma
Moberg Pharma
Mylan
Eli Lilly
Bristol Myers Squibb
Boehringer Ingelheim
Aqua Pharmaceuticals
Bausch Health
Merck
Segment by Type
Cell carcinoma
Squamous-cell Carcinoma
Melanoma
Others
Segment by Application
Hospital and Clinics
Diagnostic Centers
Cancer Research Institute
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Skin Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Skin cancer is the most common type of cancer, which arise due to uncontrolled growth of abnormal skin cells. It occurs when skin cells are damaged by unrepaired DNA or genetic defects that lead the uncontrolled growth of cells in the skin.
The global Skin Cancer market was valued at US$ 502.4 million in 2023 and is anticipated to reach US$ 727 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
Increasing incidence of skin cancer: The incidence of skin cancer is increasing worldwide, primarily due to the rise in UV exposure, aging population, and increasing awareness about skin cancer prevention and early detection. This has led to an increase in the demand for skin cancer treatment options, thereby driving the market growth.
Advances in skin cancer treatment: The development of new and innovative treatment options for skin cancer, including targeted therapies and immunotherapies, has significantly improved patient outcomes and increased the survival rates. These advancements have driven the demand for skin cancer drugs and treatment options, fueling market growth.
Rising awareness about skin cancer: The increasing awareness about skin cancer and its prevention methods has led to a significant increase in the diagnosis and treatment rates. This has propelled the demand for skin cancer drugs and treatment options, further driving market growth.
Exponential growth in the aging population: The aging population is more susceptible to skin cancer due to prolonged exposure to UV rays and other environmental factors. The rise in the aging population has led to an increase in the demand for skin cancer treatment options, fueling market growth.
Increasing health care expenditure: With the improving economy and increasing disposable income in many countries, health care expenditure is on the rise. This has led to an increase in the demand for skin cancer drugs and treatment options, further driving market growth.
This report aims to provide a comprehensive presentation of the global market for Skin Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Skin Cancer.
Report Scope
The Skin Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Skin Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Skin Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
Sun Pharma
Elekta
Varian Medical Systems
Cannabis Science
Cellceutix
LEO Pharma
Moberg Pharma
Mylan
Eli Lilly
Bristol Myers Squibb
Boehringer Ingelheim
Aqua Pharmaceuticals
Bausch Health
Merck
Segment by Type
Cell carcinoma
Squamous-cell Carcinoma
Melanoma
Others
Segment by Application
Hospital and Clinics
Diagnostic Centers
Cancer Research Institute
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Skin Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Skin Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cell carcinoma
1.2.3 Squamous-cell Carcinoma
1.2.4 Melanoma
1.2.5 Others
1.3 Market by Application
1.3.1 Global Skin Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital and Clinics
1.3.3 Diagnostic Centers
1.3.4 Cancer Research Institute
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Skin Cancer Market Perspective (2019-2030)
2.2 Skin Cancer Growth Trends by Region
2.2.1 Global Skin Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Skin Cancer Historic Market Size by Region (2019-2024)
2.2.3 Skin Cancer Forecasted Market Size by Region (2025-2030)
2.3 Skin Cancer Market Dynamics
2.3.1 Skin Cancer Industry Trends
2.3.2 Skin Cancer Market Drivers
2.3.3 Skin Cancer Market Challenges
2.3.4 Skin Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Skin Cancer Players by Revenue
3.1.1 Global Top Skin Cancer Players by Revenue (2019-2024)
3.1.2 Global Skin Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Skin Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Skin Cancer Revenue
3.4 Global Skin Cancer Market Concentration Ratio
3.4.1 Global Skin Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Skin Cancer Revenue in 2023
3.5 Skin Cancer Key Players Head office and Area Served
3.6 Key Players Skin Cancer Product Solution and Service
3.7 Date of Enter into Skin Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Skin Cancer Breakdown Data by Type
4.1 Global Skin Cancer Historic Market Size by Type (2019-2024)
4.2 Global Skin Cancer Forecasted Market Size by Type (2025-2030)
5 Skin Cancer Breakdown Data by Application
5.1 Global Skin Cancer Historic Market Size by Application (2019-2024)
5.2 Global Skin Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Skin Cancer Market Size (2019-2030)
6.2 North America Skin Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Skin Cancer Market Size by Country (2019-2024)
6.4 North America Skin Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Skin Cancer Market Size (2019-2030)
7.2 Europe Skin Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Skin Cancer Market Size by Country (2019-2024)
7.4 Europe Skin Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Skin Cancer Market Size (2019-2030)
8.2 Asia-Pacific Skin Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Skin Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Skin Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Skin Cancer Market Size (2019-2030)
9.2 Latin America Skin Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Skin Cancer Market Size by Country (2019-2024)
9.4 Latin America Skin Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Skin Cancer Market Size (2019-2030)
10.2 Middle East & Africa Skin Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Skin Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Skin Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Skin Cancer Introduction
11.1.4 Roche Revenue in Skin Cancer Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Skin Cancer Introduction
11.2.4 Novartis Revenue in Skin Cancer Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Sun Pharma
11.3.1 Sun Pharma Company Detail
11.3.2 Sun Pharma Business Overview
11.3.3 Sun Pharma Skin Cancer Introduction
11.3.4 Sun Pharma Revenue in Skin Cancer Business (2019-2024)
11.3.5 Sun Pharma Recent Development
11.4 Elekta
11.4.1 Elekta Company Detail
11.4.2 Elekta Business Overview
11.4.3 Elekta Skin Cancer Introduction
11.4.4 Elekta Revenue in Skin Cancer Business (2019-2024)
11.4.5 Elekta Recent Development
11.5 Varian Medical Systems
11.5.1 Varian Medical Systems Company Detail
11.5.2 Varian Medical Systems Business Overview
11.5.3 Varian Medical Systems Skin Cancer Introduction
11.5.4 Varian Medical Systems Revenue in Skin Cancer Business (2019-2024)
11.5.5 Varian Medical Systems Recent Development
11.6 Cannabis Science
11.6.1 Cannabis Science Company Detail
11.6.2 Cannabis Science Business Overview
11.6.3 Cannabis Science Skin Cancer Introduction
11.6.4 Cannabis Science Revenue in Skin Cancer Business (2019-2024)
11.6.5 Cannabis Science Recent Development
11.7 Cellceutix
11.7.1 Cellceutix Company Detail
11.7.2 Cellceutix Business Overview
11.7.3 Cellceutix Skin Cancer Introduction
11.7.4 Cellceutix Revenue in Skin Cancer Business (2019-2024)
11.7.5 Cellceutix Recent Development
11.8 LEO Pharma
11.8.1 LEO Pharma Company Detail
11.8.2 LEO Pharma Business Overview
11.8.3 LEO Pharma Skin Cancer Introduction
11.8.4 LEO Pharma Revenue in Skin Cancer Business (2019-2024)
11.8.5 LEO Pharma Recent Development
11.9 Moberg Pharma
11.9.1 Moberg Pharma Company Detail
11.9.2 Moberg Pharma Business Overview
11.9.3 Moberg Pharma Skin Cancer Introduction
11.9.4 Moberg Pharma Revenue in Skin Cancer Business (2019-2024)
11.9.5 Moberg Pharma Recent Development
11.10 Mylan
11.10.1 Mylan Company Detail
11.10.2 Mylan Business Overview
11.10.3 Mylan Skin Cancer Introduction
11.10.4 Mylan Revenue in Skin Cancer Business (2019-2024)
11.10.5 Mylan Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Detail
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly Skin Cancer Introduction
11.11.4 Eli Lilly Revenue in Skin Cancer Business (2019-2024)
11.11.5 Eli Lilly Recent Development
11.12 Bristol Myers Squibb
11.12.1 Bristol Myers Squibb Company Detail
11.12.2 Bristol Myers Squibb Business Overview
11.12.3 Bristol Myers Squibb Skin Cancer Introduction
11.12.4 Bristol Myers Squibb Revenue in Skin Cancer Business (2019-2024)
11.12.5 Bristol Myers Squibb Recent Development
11.13 Boehringer Ingelheim
11.13.1 Boehringer Ingelheim Company Detail
11.13.2 Boehringer Ingelheim Business Overview
11.13.3 Boehringer Ingelheim Skin Cancer Introduction
11.13.4 Boehringer Ingelheim Revenue in Skin Cancer Business (2019-2024)
11.13.5 Boehringer Ingelheim Recent Development
11.14 Aqua Pharmaceuticals
11.14.1 Aqua Pharmaceuticals Company Detail
11.14.2 Aqua Pharmaceuticals Business Overview
11.14.3 Aqua Pharmaceuticals Skin Cancer Introduction
11.14.4 Aqua Pharmaceuticals Revenue in Skin Cancer Business (2019-2024)
11.14.5 Aqua Pharmaceuticals Recent Development
11.15 Bausch Health
11.15.1 Bausch Health Company Detail
11.15.2 Bausch Health Business Overview
11.15.3 Bausch Health Skin Cancer Introduction
11.15.4 Bausch Health Revenue in Skin Cancer Business (2019-2024)
11.15.5 Bausch Health Recent Development
11.16 Merck
11.16.1 Merck Company Detail
11.16.2 Merck Business Overview
11.16.3 Merck Skin Cancer Introduction
11.16.4 Merck Revenue in Skin Cancer Business (2019-2024)
11.16.5 Merck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
